MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01C8CBA3.2F7F2A70"

Questo documento è una pagina Web in file unico, nota anche come archivio Web. La visualizzazione di questo messaggio indica che il browser o l'editor in uso non supporta gli archivi Web. Scaricare un browser che supporti gli archivi Web, come Microsoft Internet Explorer.

------=_NextPart_01C8CBA3.2F7F2A70
Content-Location: file:///C:/11195605/dopingnorme.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dus-ascii">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 11">
<meta name=3DOriginator content=3D"Microsoft Word 11">
<link rel=3DFile-List href=3D"dopingnorme_file/filelist.xml">
<link rel=3DEdit-Time-Data href=3D"dopingnorme_file/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>Fonte: www</title>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"metricconverter"/>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"PersonName"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>carmelo</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>carmelo</o:LastAuthor>
  <o:Revision>3</o:Revision>
  <o:TotalTime>5</o:TotalTime>
  <o:Created>2008-06-11T07:06:00Z</o:Created>
  <o:LastSaved>2008-06-11T07:11:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>1247</o:Words>
  <o:Characters>7111</o:Characters>
  <o:Lines>59</o:Lines>
  <o:Paragraphs>16</o:Paragraphs>
  <o:CharactersWithSpaces>8342</o:CharactersWithSpaces>
  <o:Version>11.5606</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:HyphenationZone>14</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:DrawingGridHorizontalSpacing>6 pt</w:DrawingGridHorizontalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>2</w:DisplayHorizontalDrawingGridEve=
ry>
  <w:DisplayVerticalDrawingGridEvery>2</w:DisplayVerticalDrawingGridEvery>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" LatentStyleCount=3D"156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
a:link, span.MsoHyperlink
	{color:maroon;
	mso-text-animation:none;
	font-weight:bold;
	text-decoration:none;
	text-underline:none;
	text-decoration:none;
	text-line-through:none;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-margin-top-alt:auto;
	margin-right:0cm;
	mso-margin-bottom-alt:auto;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:70.85pt 2.0cm 2.0cm 2.0cm;
	mso-header-margin:35.45pt;
	mso-footer-margin:35.45pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
 /* List Definitions */
 @list l0
	{mso-list-id:105974818;
	mso-list-template-ids:711771366;}
@list l0:level1
	{mso-level-number-format:image;
	list-style-image:url("PicExportError");
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:307323645;
	mso-list-template-ids:-1211568914;}
@list l1:level1
	{mso-level-number-format:image;
	list-style-image:url("PicExportError");
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l1:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2
	{mso-list-id:1891333920;
	mso-list-template-ids:-1211568914;}
@list l2:level1
	{mso-level-number-format:image;
	list-style-image:url("PicExportError");
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l2:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l2:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Tabella normale";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"3074"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DIT link=3Dmaroon vlink=3Dpurple style=3D'tab-interval:35.4pt'>

<div class=3DSection1>

<p class=3DMsoNormal align=3Dright style=3D'text-align:right'><b><span
style=3D'font-family:Arial;color:black'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dright style=3D'text-align:right'><b><span
style=3D'font-family:Arial;color:black'>Fonte:</span></b> <b><span
style=3D'font-family:Arial;color:black'>www.ministerosalute.it<o:p></o:p></=
span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b><span
style=3D'font-size:18.0pt;font-family:Arial;color:blue'><o:p>&nbsp;</o:p></=
span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><b><span
style=3D'font-size:18.0pt;font-family:Arial;color:blue'><o:p>&nbsp;</o:p></=
span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'text-align:center'><span class=
=3DGramE><b><span
style=3D'font-size:18.0pt;font-family:Arial;color:blue'>Che cos'&egrave; il
doping</span></b></span><b><span style=3D'font-size:18.0pt;font-family:Aria=
l;
color:blue'><o:p></o:p></span></b></p>

<p class=3DMsoNormal><span style=3D'font-family:Arial;color:#666666'><!--[i=
f gte vml 1]><v:shapetype
 id=3D"_x0000_t75" coordsize=3D"21600,21600" o:spt=3D"75" o:preferrelative=
=3D"t"
 path=3D"m@4@5l@4@11@9@11@9@5xe" filled=3D"f" stroked=3D"f">
 <v:stroke joinstyle=3D"miter"/>
 <v:formulas>
  <v:f eqn=3D"if lineDrawn pixelLineWidth 0"/>
  <v:f eqn=3D"sum @0 1 0"/>
  <v:f eqn=3D"sum 0 0 @1"/>
  <v:f eqn=3D"prod @2 1 2"/>
  <v:f eqn=3D"prod @3 21600 pixelWidth"/>
  <v:f eqn=3D"prod @3 21600 pixelHeight"/>
  <v:f eqn=3D"sum @0 0 1"/>
  <v:f eqn=3D"prod @6 1 2"/>
  <v:f eqn=3D"prod @7 21600 pixelWidth"/>
  <v:f eqn=3D"sum @8 21600 0"/>
  <v:f eqn=3D"prod @7 21600 pixelHeight"/>
  <v:f eqn=3D"sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok=3D"f" gradientshapeok=3D"t" o:connecttype=3D"rect"/>
 <o:lock v:ext=3D"edit" aspectratio=3D"t"/>
</v:shapetype><v:shape id=3D"_x0000_i1025" type=3D"#_x0000_t75" alt=3D"" st=
yle=3D'width:3pt;
 height:3.75pt'>
 <v:imagedata src=3D"dopingnorme_file/image001.gif" o:href=3D"http://www.mi=
nisterosalute.it/antiDoping/images/tab2_ang2.gif"/>
</v:shape><![endif]--><![if !vml]><img width=3D4 height=3D5
src=3D"dopingnorme_file/image001.gif" v:shapes=3D"_x0000_i1025"><![endif]><=
o:p></o:p></span></p>

<p class=3DMsoNormal><!--[if gte vml 1]><v:shape id=3D"_x0000_s1026" type=
=3D"#_x0000_t75"
 alt=3D"" style=3D'position:absolute;margin-left:0;margin-top:-92.75pt;widt=
h:64.5pt;
 height:64.5pt;z-index:1;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal:left;mso-position-vertical-relative:line'
 o:allowoverlap=3D"f">
 <v:imagedata src=3D"dopingnorme_file/image002.gif" o:title=3D"C_17_pagineA=
ree_130_paragrafi_paragrafo_0_immagine"/>
 <w:wrap type=3D"square"/>
</v:shape><![endif]--><![if !vml]><img width=3D86 height=3D86
src=3D"dopingnorme_file/image002.gif" align=3Dleft v:shapes=3D"_x0000_s1026=
"><![endif]><span
style=3D'font-family:Arial;color:black'><br>
<br>
Il fenomeno &quot;doping&quot; &egrave; un problema riguardante non solo <s=
pan
class=3DSpellE>l&acute;etica</span> sportiva ma anche la salute pubblica. <=
br>
&quot;Costituiscono doping la somministrazione o <span class=3DSpellE>l&acu=
te;assunzione</span>
o la <span class=3DGramE>somministrazione</span> di farmaci o di sostanze
biologicamente o <span class=3DSpellE>farmacologicamente</span> attive e <s=
pan
class=3DSpellE>l&acute;adozione</span> o la sottoposizione a pratiche medic=
he non
giustificate da condizioni patologiche e idonee a modificare le condizioni
psicofisiche o biologiche <span class=3DSpellE>dell&acute;organismo</span> =
al
fine di alterare le prestazioni agonistiche degli atleti.&quot;<br>
<span class=3DSpellE>E&acute;</span> quanto cita <span class=3DSpellE>l&acu=
te;art</span>.
1 della <a
href=3D"http://www.ministerosalute.it/imgs/C_17_normativa_652_allegato.pdf"
title=3D"link a Legge 14 dicembre 2000"><b>Legge 14 dicembre 2000, n. 376</=
b></a>
che disciplina in Italia la tutela sanitaria delle attivit&agrave; sportive=
 e
della lotta contro il doping. Il doping &egrave; un reato penale, punito fi=
no a
tre anni di reclusione (che possono diventare di pi&ugrave; se insorgono da=
nni
effettivi per la salute), se ad essere indotto ad assumere sostanze vietate=
 per
doping &egrave; un minorenne o se, a distribuire le sostanze, &egrave; un
dipendente <span class=3DGramE>del CONI</span>. Solo <span class=3DGramE>in
presenza</span> di condizioni patologiche <span class=3DSpellE>dell&acute;a=
tleta</span>
documentate e certificate da un medico e verificata <span class=3DSpellE>l&=
acute;assenza</span>
di pericoli per la salute, &egrave; consentito un trattamento specifico con
sostanze vietate per doping e la possibilit&agrave; di partecipare ugualmen=
te
alle competizione sportiva. <span class=3DGramE>Ma</span> anche in questo c=
aso il
trattamento deve rispondere a specifiche esigenze terapeutiche e la
documentazione deve essere conservata e tenuta sempre a disposizione <span
class=3DSpellE>dall&acute;atleta</span>. Il controllo anti-doping vero e pr=
oprio
sulle competizioni e sulle attivit&agrave; sportive spetta ad alcuni labora=
tori
accreditati dal <a href=3D"http://www.olympic.org/uk/index_uk.asp"
title=3D"link esterno a sito CIO"><b>Comitato Internazionale Olimpico </b><=
/a>(CIO).
<br>
<br>
<span class=3DGramE>La lista delle sostanze biologicamente e <span class=3D=
SpellE>farmacologicamente</span>
attive che circolano negli spogliatoi e nelle palestre &egrave; molto lunga=
</span>.
<br>
Si possono raggruppare in tre categorie principali: <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-margin-top-alt:auto;mso-margin-bottom-alt=
:auto;
margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:li=
st 36.0pt'><![if !supportLists]><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black'><sp=
an
style=3D'mso-list:Ignore'><img width=3D13 height=3D13 src=3DPicExportError =
alt=3D"*"><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
 </span></span></span><![endif]><span
class=3DGramE><span style=3D'font-family:Arial;color:black'>i</span></span>=
<span
style=3D'font-family:Arial;color:black'> farmaci non vietati per doping, ma
utilizzati per scopi diversi da quelli autorizzati, <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-margin-top-alt:auto;mso-margin-bottom-alt=
:auto;
margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:li=
st 36.0pt'><![if !supportLists]><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black'><sp=
an
style=3D'mso-list:Ignore'><img width=3D13 height=3D13 src=3DPicExportError =
alt=3D"*"><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
 </span></span></span><![endif]><span
class=3DGramE><span style=3D'font-family:Arial;color:black'>i</span></span>=
<span
style=3D'font-family:Arial;color:black'> farmaci vietati per doping <o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'mso-margin-top-alt:auto;mso-margin-bottom-alt=
:auto;
margin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:li=
st 36.0pt'><![if !supportLists]><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black'><sp=
an
style=3D'mso-list:Ignore'><img width=3D13 height=3D13 src=3DPicExportError =
alt=3D"*"><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
 </span></span></span><![endif]><span
class=3DGramE><span style=3D'font-family:Arial;color:black'>gli</span></spa=
n><span
style=3D'font-family:Arial;color:black'> integratori, ovvero i prodotti
salutistici, vale a dire tutti quei prodotti che servono a reintegrare
eventuali perdite di macro e <span class=3DSpellE>micronutrienti</span> (sa=
li,
aminoacidi, vitamine). <o:p></o:p></span></p>

<p><span style=3D'font-family:Arial;color:black'>Per quanto riguarda <span
class=3DSpellE>l&acute;<strong><span style=3D'font-family:Arial'>impiego</s=
pan></strong></span><strong><span
style=3D'font-family:Arial'> di farmaci al di fuori delle indicazioni</span=
></strong>
per <span class=3DGramE>le quali</span> sono stati sintetizzati, &egrave;
opportuno ricordare che la loro somministrazione a persone non malate &egra=
ve;
sempre pericolosa in quanto priva di finalit&agrave; terapeutica, scopo
fondamentale di un medicamento. Tra i farmaci pi&ugrave; usati gli
antinfiammatori non <span class=3DSpellE>steroidei</span>, gli integratori =
e i
prodotti <span class=3DSpellE>erboristici</span> <span class=3DGramE>o</spa=
n> omeopatici.
<span class=3DGramE>Come </span>effetti negativi <span class=3DSpellE>possi=
bilie</span>
comparsa di gravi reazioni avverse. <br>
<br>
Tra i <strong><span style=3D'font-family:Arial'>farmaci vietati per doping<=
/span></strong>,
<st1:PersonName ProductID=3D"la Eritropoietina" w:st=3D"on"><span class=3DG=
ramE>la </span><span
 class=3DSpellE>Eritropoietina</span></st1:PersonName> (EPO) e i suoi deriv=
ati,
gli anabolizzanti e gli stimolanti. <br>
<br>
<st1:PersonName ProductID=3D"La EPO" w:st=3D"on"><span class=3DGramE>La </s=
pan><strong><span
 style=3D'font-family:Arial'>EPO</span></strong></st1:PersonName><strong><s=
pan
style=3D'font-family:Arial'> </span></strong>&egrave; una <span class=3DSpe=
llE>glicoproteina</span>
prodotta dal rene che agisce stimolando la proliferazione e la maturazione =
di
globuli rossi. Il suo uso in medicina <span class=3DGramE>&egrave; relativo=
 al</span>
trattamento <span class=3DSpellE>dell&acute;anemia</span> nei pazienti con
insufficienza renale cronica. <br>
Per questo motivo (ossia per la sua capacit&agrave; di regolare la produzio=
ne
dei globuli rossi e dunque di aumentare <span class=3DSpellE>l&acute;apport=
o</span>
<span class=3DGramE>di </span>ossigeno nel sangue), &egrave; molto diffusa =
tra
ciclisti e maratoneti, costretti a prestazioni atletiche di lunga durata. Il
ricorso <span class=3DSpellE>all&acute;EPO</span> comporta rischi non
trascurabili per la salute dell'atleta, correlati all'aumento della
viscosit&agrave; del sangue e della pressione arteriosa, come ictus, trombo=
si e
infarto del miocardio.<br>
Nella pratica sportiva, l'utilizzo di steroidi anabolizzanti accresce lo
sviluppo muscolare, potenziando la forza fisica e la resistenza allo sforzo.
Gli effetti negativi includono tossicit&agrave; a carico del fegato, degli
apparati cardiovascolare <span class=3DGramE>e</span> endocrino, sviluppo di
tumori e disturbi psichiatrici. <br>
Gli <span class=3DGramE><strong><span style=3D'font-family:Arial'>stimolant=
i</span></strong></span><strong><span
style=3D'font-family:Arial'> </span></strong>(ad esempio amfetamine, cocain=
a, <span
class=3DSpellE>efedrina</span>, <span class=3DSpellE>pseudoefredina</span>,
caffeina) sono impiegati ad uso doping in quanto aumentano il livello di
vigilanza, riducono il senso di fatica e possono aumentare l'agonismo e
l'aggressivit&agrave;. Altri effetti negativi comprendono disturbi
cardiovascolari fino ad aritmie anche mortali e veri e propri disturbi neur=
ologici
e psichiatrici. <o:p></o:p></span></p>

<p><span style=3D'font-family:Arial;color:black'>Gli <strong><span
style=3D'font-family:Arial'>integratori alimentari</span></strong> <span
class=3DGramE>vengono</span> considerati come prodotti appartenenti <span
class=3DSpellE>all&acute;area</span> alimentare, a base di vitamine, minera=
li e
altre sostanze di interesse nutrizionale e fisiologico. In ambito sportivo =
<span
class=3DGramE>vengono</span> spesso usati con la speranza di incrementare la
massa muscolare, ridurre il grasso corporeo, aumentare la velocit&agrave;,
migliorare la resistenza ed avere un recupero pi&ugrave; rapido. Sono
facilmente reperibili in quanto presenti anche sugli scaffali dei supermerc=
ati.
<br>
Dal punto di vista legale, non essendo considerati farmaci, non sono sottop=
osti
ad una rigorosa regolamentazione. Per quelli ad uso sportivo &egrave; previ=
sta <span
class=3DSpellE>l&acute;autorizzazione</span> ministeriale, per altri la sem=
plice
notifica presso il Ministero, ma ve ne sono innumerevoli altri ancora, che
vanno sotto il nome di prodotti salutistici (dai <span class=3DGramE>prodot=
ti</span>
<span class=3DSpellE>erboristici</span> e dietetici a quelli omeopatici, da=
gli
antiossidanti alle tavolette energetiche). <br>
<br>
<strong><span style=3D'font-family:Arial'>I metodi proibiti </span></strong=
><b><br>
<br>
</b>Le pratiche di doping pi&ugrave; diffuse sono il <strong><span
style=3D'font-family:Arial'>doping ematico</span></strong> e le <strong><sp=
an
style=3D'font-family:Arial'>manipolazioni chimiche e fisiche dei campioni <=
span
class=3DGramE>di </span>urina</span></strong>. <br>
<br>
Nel primo caso, <span class=3DSpellE>all&acute;atleta</span> <span class=3D=
GramE>vengono</span>
somministrati, per via endovenosa, sostanze di sintesi correlate <span
class=3DSpellE>all&acute;EPO</span> che migliorano il trasporto di ossigeno=
 nel
sangue. <br>
<span class=3DSpellE><span class=3DGramE>Un&acute;altra</span></span><span
class=3DGramE> pratica</span> &egrave; quella <span class=3DSpellE>dell&acu=
te;autotrasfusione</span>:
<span class=3DSpellE>l&acute;atleta</span> cio&egrave;, si sottopone a un
prelievo di sangue, che, dopo essere stato adeguatamente conservato e non
appena i globuli rossi sono tornati a livello normale, gli viene trasfuso
nuovamente, ottenendo cos&igrave; un incremento del numero dei globuli ross=
i. <br>
I rischi connessi al doping ematico <span class=3DGramE>includono reazioni
allergiche, possibile trasmissione di malattie infettive, sovraccarico</spa=
n>
del sistema circolatorio e shock metabolico. <br>
<br>
Per manipolazione <span class=3DSpellE>farmacologica</span>, chimica o fisi=
ca
quale metodo doping <span class=3DGramE>si </span>intende &quot;<span
class=3DSpellE>l&acute;uso</span> di sostanze e di metodi in grado di alter=
are
l'integrit&agrave; e la validit&agrave; dei campioni di urine utilizzati pe=
r i
controlli antidoping&quot;. <br>
Le manipolazioni <span class=3DGramE>vanno dallo scambio dei campioni <span
class=3DSpellE>d&acute;urina</span> alla diluizione con altri liquidi, fino=
 <span
class=3DSpellE>all&acute;inserimento</span> nella vescica, tramite catetere=
, <span
class=3DSpellE>dell&acute;urina</span></span> altrui. Possono inoltre essere
usati i diuretici chiamati non a caso mascheranti, perch&eacute; in grado di
eliminare pi&ugrave; velocemente, favorendo la diuresi, le sostanze proibite
rintracciabili ai test antidoping. Inoltre, la prima cosa che si esamina nei
campioni <span class=3DGramE>di </span>urina &egrave; il <span class=3DSpel=
lE>pH</span>,
in quanto &egrave; possibile facilitare <span class=3DSpellE>l&acute;elimin=
azione</span>
di farmaci vietati <span class=3DSpellE>alcalinizzando</span> o acidificand=
o <span
class=3DSpellE>l&acute;urina</span>; la seconda &egrave; la densit&agrave;:=
 <span
class=3DSpellE>un&acute;urina</span> con basso peso specifico, pu&ograve;
indicare una manipolazione finalizzata ad abbassare la concentrazione di un
farmaco al di sotto della soglia di rilevazione. <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'font-family:Arial;color:black'>Un contr=
assegno
sulle confezioni dei medicinali regolarmente in vendita, ma considerati
potenzialmente <span class=3DGramE>positivi</span> ai controlli antidoping =
mette
in guardia atleti e cittadini sugli eventuali effetti <span class=3DSpellE>=
dopanti</span>
delle sostanze in questione. <br>
<br>
Il <a href=3D"http://www.ministerosalute.it/imgs/C_17_normativa_656_allegat=
o.pdf"
title=3D"link a DM 24 settembre 2003"><b>Decreto&nbsp;24 settembre 2003 </b=
></a>modificato
dal <a href=3D"http://www.ministerosalute.it/imgs/C_17_normativa_649_allega=
to.pdf"
title=3D"link a DM 30 aprile 2004"><span class=3DGramE><b>Decreto</b></span=
><b> 30
aprile 2004 </b></a>prevede che <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-margin-top-alt:auto;mso-margin-bottom-alt=
:auto;
margin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:li=
st 36.0pt'><![if !supportLists]><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black'><sp=
an
style=3D'mso-list:Ignore'><img width=3D13 height=3D13 src=3DPicExportError =
alt=3D"*"><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
 </span></span></span><![endif]><span
class=3DSpellE><span class=3DGramE><span style=3D'font-family:Arial;color:b=
lack'>l</span></span><span
style=3D'font-family:Arial;color:black'>&acute;etichettatura</span></span><=
span
style=3D'font-family:Arial;color:black'> della scatola deve includere un
pittogramma di forma circolare del diametro complessivo di <st1:metricconve=
rter
ProductID=3D"17 millimetri" w:st=3D"on">17 millimetri</st1:metricconverter>,
riportante un simbolo di divieto, di colore rosso con all'interno la scritta
DOPING <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-margin-top-alt:auto;mso-margin-bottom-alt=
:auto;
margin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:li=
st 36.0pt'><![if !supportLists]><span
style=3D'font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:black'><sp=
an
style=3D'mso-list:Ignore'><img width=3D13 height=3D13 src=3DPicExportError =
alt=3D"*"><span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
 </span></span></span><![endif]><span
class=3DGramE><span style=3D'font-family:Arial;color:black'>il</span></span=
><span
style=3D'font-family:Arial;color:black'> foglio illustrativo deve riportare=
 al
paragrafo &quot;Avvertenze speciali&quot; la frase &quot;Per chi svolge
attivit&agrave; sportiva: l'uso del farmaco senza necessit&agrave; terapeut=
ica
costituisce doping e pu&ograve; determinare comunque positivit&agrave; ai t=
est
anti-doping&quot;. <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'font-family:Arial;color:black'>I farmac=
isti, ma
anche <span class=3DGramE>coloro che sono</span> autorizzati <span class=3D=
SpellE>all&acute;immissione</span>
in commercio di questi prodotti dovranno trasmettere entro il 31 gennaio di
ogni anno al Ministero della Salute i dati relativi <span class=3DSpellE>al=
l&acute;anno</span>
precedente delle quantit&agrave; prodotte, importate, distribuite e vendute=
 di
ciascun farmaco.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'font-family:Arial;color:#666666'><!--[i=
f gte vml 1]><v:shape
 id=3D"_x0000_i1026" type=3D"#_x0000_t75" alt=3D"" style=3D'width:6pt;heigh=
t:6pt'>
 <v:imagedata src=3D"dopingnorme_file/image003.gif" o:href=3D"http://www.mi=
nisterosalute.it/antiDoping/images/tab2_ang3.gif"/>
</v:shape><![endif]--><![if !vml]><img border=3D0 width=3D8 height=3D8
src=3D"dopingnorme_file/image003.gif" v:shapes=3D"_x0000_i1026"><![endif]><=
o:p></o:p></span></p>

<p><span style=3D'font-family:Arial;color:black'><o:p>&nbsp;</o:p></span></=
p>

<p><span style=3D'font-family:Arial;color:black'><o:p>&nbsp;</o:p></span></=
p>

<p class=3DMsoNormal><span style=3D'font-family:Arial;color:black'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal><span style=3D'font-family:Arial'><o:p>&nbsp;</o:p></s=
pan></p>

</div>

</body>

</html>

------=_NextPart_01C8CBA3.2F7F2A70
Content-Location: file:///C:/11195605/dopingnorme_file/image003.gif
Content-Transfer-Encoding: base64
Content-Type: image/gif

R0lGODlhCAAIAMQAALe3t+zs7Pj4+Pn5+f7+/ufn5+rq6vv7+7W1tejo6Pf39+3t7f7+/ra2tra2
tuvr6/f39/Pz8+7u7vn5+fj4+O/v7+np6fDw8PPz8+bm5vDw8Ofn5+Xl5ba2tvT09P///ywAAAAA
CAAIAAAFLyAiDBRETUrkeRi2ep1WXZJ2VV/3WItlBJ/chpPgZIIMwMfxaQSDhw/hGSxkOJsQADs=

------=_NextPart_01C8CBA3.2F7F2A70
Content-Location: file:///C:/11195605/dopingnorme_file/image001.gif
Content-Transfer-Encoding: base64
Content-Type: image/gif

R0lGODlhBAAFALMAAP7+/v39/ba2tra2tv7+/v7+/v///wAAAJGRka2trYuLi0dHRzQ0NFFRUX9/
f/39/SH5BAEAAAoALAAAAAAEAAUAAAQK0MgxlRlK4cxVBAA7

------=_NextPart_01C8CBA3.2F7F2A70
Content-Location: file:///C:/11195605/dopingnorme_file/image002.gif
Content-Transfer-Encoding: base64
Content-Type: image/gif
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------=_NextPart_01C8CBA3.2F7F2A70
Content-Location: file:///C:/11195605/dopingnorme_file/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../dopingnorme.htm"/>
 <o:File HRef=3D"image001.gif"/>
 <o:File HRef=3D"image002.gif"/>
 <o:File HRef=3D"image003.gif"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01C8CBA3.2F7F2A70--

